<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03785236</url>
  </required_header>
  <id_info>
    <org_study_id>NL52630.091.15</org_study_id>
    <nct_id>NCT03785236</nct_id>
  </id_info>
  <brief_title>Visualizing Beta Cells After Islet Transplantation</brief_title>
  <acronym>GLP1-transpl</acronym>
  <official_title>Visualizing Beta Cells After Intrahepatic Islet of Langerhans Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with type 1 diabetes (T1D) that have undergone islet of Langerhans&#xD;
      transplantation or are on the waiting list for transplantation, Ga-68-exendin PET imaging is&#xD;
      performed to study the visualization of transplanted islet grafts in patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detecting damage to islets with a reliable imaging technique could be important for improving&#xD;
      islet survival after transplantation. This could lead to better patient outcomes which would&#xD;
      be of great interest for the treatment of type 1 diabetes. In order to assess the possibility&#xD;
      of visualizing transplanted islet grafts with Ga-68-NODAGA-exendin-4 PET, a proof-of -concept&#xD;
      study is performed in 10 patients with type 1 diabetes who have undergone intrahepatic islet&#xD;
      transplantation with biochemically proven functional islet grafts and 5 patients with type 1&#xD;
      diabetes who are on the waiting list for islet transplantation. The investigators propose to&#xD;
      determine the uptake of the radiolabeled tracer and compare it to functionality of the islet&#xD;
      grafts. These highly relevant data will provide us with more information on the suitability&#xD;
      of GLP-1 receptor imaging for monitoring of transplanted islet mass.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 6, 2016</start_date>
  <completion_date type="Anticipated">January 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic uptake of 68Ga-NODAGA-exendin-4</measure>
    <time_frame>1 year</time_frame>
    <description>Hepatic uptake of 68Ga-NODAGA-exendin-4 obtained by quantitative analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Islet graft function</measure>
    <time_frame>1 year</time_frame>
    <description>Correlation of tracer uptake and islet graft function</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Tx-group</arm_group_label>
    <description>T1D patients that received islet of Langerhans transplantation (Tx) at least 3 months earlier</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>T1D patients that await islet of Langerhans transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>68Ga-NODAGA-exendin PET/CT</intervention_name>
    <description>68Ga-NODAGA-exendin PET/CT</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Tx-group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The population consists of 10 individuals with type 1 diabetes patients who have undergone&#xD;
        intrahepatic islet transplantation at least 3 months earlier at. Furthermore, 5 T1D&#xD;
        patients without an islet transplant will be included as a control for uptake of the&#xD;
        radiotracer in the liver. All participating individuals need to be 18 years or older. In&#xD;
        total, 15 participants will be included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Tx-group:&#xD;
&#xD;
          -  &gt;18 years old&#xD;
&#xD;
          -  T1D patient undergone islet transplantation&#xD;
&#xD;
          -  Clinically proven functional islet graft&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Control group:&#xD;
&#xD;
          -  &gt;18 years old&#xD;
&#xD;
          -  T1D patients who are on the waiting list for islet transplantation&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with synthetic exendin or Dipeptidyl-Peptidase IV inhibitors within the last&#xD;
             3 months&#xD;
&#xD;
          -  Breast feeding&#xD;
&#xD;
          -  Pregnancy or the wish to become pregnant within 6 months&#xD;
&#xD;
          -  Kidney disease&#xD;
&#xD;
          -  Liver disease&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  No signed informed consent&#xD;
&#xD;
        Exclusion criteria for MR:&#xD;
&#xD;
          -  fragments, clips or devices in brain, eyes, spinal canal&#xD;
&#xD;
          -  Implantable defibrillator or pacemaker (wires)&#xD;
&#xD;
          -  Mandibular magnetic implants&#xD;
&#xD;
          -  Neurostimulator, bladder stimulator, non-removable insulin pump&#xD;
&#xD;
          -  Metal tissue-expander in chest&#xD;
&#xD;
          -  Cochlear implant&#xD;
&#xD;
          -  Ossicular replacement prosthesis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Tom JP Jansen, MSc</last_name>
    <phone>0031243667244</phone>
    <email>tom.jp.jansen@radboudumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Radboud university medical center</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom JP Jansen, MSc</last_name>
      <phone>0031243667244</phone>
      <email>tom.jp.jansen@radboudumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Martin Gotthardt, Prof. Dr.</last_name>
      <phone>0031243619061</phone>
      <email>Martin.Gotthardt@radboudumc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olof Eriksson, Dr.</last_name>
      <phone>0046707903054</phone>
      <email>olof.eriksson@ilk.uu.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>December 20, 2018</study_first_submitted>
  <study_first_submitted_qc>December 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2018</study_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

